1625 / 1851
CMS4 stemlike
Del Rio M, et al. Molecular subtypes of metastatic
colorectal cancer are associated with patient
response to irinotecan-based therapies. Eur J
Cancer. 2017 May;76:68-75
87% response to FOLFIRI in CMS4
Song N, et al. Clinical Outcome From Oxaliplatin
Treatment in Stage II/III Colon Cancer According
to Intrinsic Subtypes: Secondary Analysis of
NSABP C-07/NRG Oncology Randomized Clinical
Trial. JAMA Oncol. 2016 Sep 1;2(9):1162-9
Lack of benefit from Oxaliplatin/poor prognosis in CMS4